No.2 Zhongxin Street, Louzi Zhuang, Jinzhanxiang Chaoyang District
Phone: +86 10 8431-9330
Fax: +86 10 8431-9330
Department/ Name Address
Jerry Liu firstname.lastname@example.org
W.H.P.M., Inc., established in 1992, is a privately held corporation headquartered at El Monte, California, only 15 minutes away from downtown Los Angeles. The Company is a pioneer in the research and development of one-step rapid membrane tests. It has been designated a registered GMP facility for in vitro diagnostic medical devices by the FDA.
W.H.P.M. is established upon over a decade of research in the bio-technological industry. Its scientific professional team has applied these years of R&D experience to their development of one-step membrane immunoassay tests. With the strong support of our sister company, WHPM Bioresearch Technology Co., Ltd., W.H.P.M. has continuously researched, developed, and produced high quality rapid test systems that have not only revolutionized the pharmaceutical industry, but have also set new industry standards and guidelines.
Our current product leader is Hemosure®, a trade name recognized worldwide in immunological fecal occult blood test (IFOBT). In year 2001, W.H.P.M. was proudly designated a sponsor in providing high quality immunological fecal occult blood tests for a large colorectal cancer-screening program; over 20,000 people in Beijing, China took part in the study. In April 2004, the Company sponsored another colorectal cancer-screening program in Hangzhou, China, in which over 60,000 people participated. Upon completion, these two recent studies together will surpass any previous clinically related studies in the world in terms of size and scope.
Through continuing clinical development, W.H.P.M. is committed to building a portfolio of quality products. Using only the highest standards, we deliver our products to the marketplace at highly competitive and affordable prices. Our mission statement clearly identifies and sets the direction for our company: “It is our goal to continually research and develop novel tests systems to enhance the quality of life.”